WEDI, ASC issue ICD-10 prep brief

The Workgroup for Electronic Data Interchange (WEDI) released an ICD-10 issue brief co-written with ASC X12 to help the healthcare industry better undertand where to focus transaction testing to ensure that codes are correctly placed and formatted within the transactions.

WEDI and ASC X12’s issue brief, ICD-10 Impact to HIPAA Transactions, states that, as part of the ICD-10 testing process, it is imperative to assure that ICD-10-CM and ICD-10-PCS codes are accurately passed from providers through to payers within the transactions required under HIPAA to exchange diagnosis and procedure information. The issue brief provides information on the transactions that are impacted by ICD-10 as well as the placement of the codes within the transactions. Knowing where all of the touch points are will help facilitate implementation and testing. 

“Although it can be argued that implementation of version 5010 of the ASC X12 transactions tested the format that will be used to carry ICD-10 codes, the industry did not focus on assuring that ICD-10 codes were correctly assigned and reflected on these transactions or that ICD-10 codes were correctly processed in front end applications,” said Jim Daley, WEDI chairman. “This document will help highlight the transactions and content that will need to be validated as part of the ICD-10 testing effort.” 

The ICD-10 Impact to HIPAA Transactions issue brief was written by WEDI’s ICD-10 Workgroup and ASC X12 staff members and is available for download on the WEDI website.

 

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.